DOCSLIB.ORG

HP Layout 1-21-04 to Print

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
HP Layout 1-21-04 to Print Winter 2004 Department of Surgery healthpoints NewYork-Presbyterian ALL THE POSSIBILITIES OF MODERN MEDICINEE DIABETES Knowledge is Power ALSO IN THIS ISSUE: in a Complex Disease Approximately 17 million people in the United States have the disease. While an estimated 11.1 million have been diagnosed, 5.9 million people remain unaware that POSITRON EMISSION they have the condition. It is the fifth leading cause of death by disease in the U.S.— TOMOGRAPHY (PET) contributing to the deaths of more than 210,000 Americans each year. And its origin Approved for the Fight remains a mystery. Against Thyroid Cancer Diabetes is a complex disease which results from the body’s inability to create or page 2 properly use insulin. A hormone produced by the pancreas, insulin helps the body convert sugar, starches, and other food into energy. If the body doesn’t make enough insulin or if the insulin doesn’t work the way it should, glucose (sugar) cannot enter into the body’s cells. Instead, ISLET CELL glucose remains in the TRANSPLANTATION bloodstream, raising the The Search for a Cure blood sugar level and for Type 1 Diabetes ultimately causing page 7 diabetes. The signs of diabetes are often subtle, which can make detection of the disease a greater AIDING THE HEART challenge. Some Medicare Approves common symptoms LVADs as Destination include excessive thirst, Diabetes strikes people of all ages, races, and genders. Therapy frequent urination, page 8 unusual weight loss, increased fatigue, slow wound healing, extreme hunger, and blurry vision. However, individuals who experience none of these signs may still have diabetes. “Until the blood sugar is elevated, diabetes has no symptoms,”says Robin Goland, MD, THE MANY FACES Director, Naomi Berrie Diabetes Center at Columbia University Medical Center. BEHIND “A major misconception about diabetes is that if you have no symptoms, you cannot A MISSION have the disease. The importance of screening people can’t be overemphasized,” Dr. Jeffrey Ascherman's Dr. Goland adds. Humanitarian Mission Diabetes is typically detected through a routine blood glucose test or a urine exam. to China People can develop diabetes at any age, and it manifests itself in different forms— page 9 which further contributes to its complexity. While there is no cure for diabetes, individuals with the disease can live long and healthy lives if they take control of the disease. When it comes to diabetes, knowledge is definitely power. If patients take care of themselves with exercise, watch their diet, and maintain a healthy lifestyle, treatment continued on page 4 Positron Emission Tomography (PET) A GROWING CONCERN cancers and can typically be treated and chemotherapy. Patients should According to the American Cancer successfully if detected early. review these options with their physician Society, approximately 22,000 Americans While no one knows the cause of to select the best treatment approach for were diagnosed with thyroid cancer in thyroid cancer, certain risk factors, such their individual case. 2003 and 1,500 will die from the disease. as family history, gender (female), age Thyroid cancer is two to three times more (over 40), and race (white) are associated PET AND THYROID CANCER common in women than men. Unlike with the disease. Children who experience Follow-up care is a critical component of most cancers, the incidence of thyroid external irradiation to the head and neck thyroid cancer treatment, since 30 percent cancer has actually increased over the past also have an increased risk. Studies of patients will experience a recurrence of few years. revealed a sharp increase in childhood the disease. Today, there are nearly A butterfly-shaped gland located thyroid cancer rates followed exposure to 300,000 thyroid cancer survivors in the in the front of the neck, the thyroid the Chernobyl nuclear accident. United States. These patients undergo produces hormones that affect heart rate, A range of options exist for treating regular screenings to detect recurrences, energy level, and body temperature. thyroid cancer, including surgery, thyroid including: The vast majority of thyroid tumors— hormone therapy, radioactive iodine ● physical examinations 131 80-90%—are papillary or follicular therapy (I ), external radiation therapy, ● thyroglobulin studies (a protein pro- duced by the thyroid, thyroglobulin becomes elevated in individuals with thyroid cancer) RENÉ PEREZ 131 ● diagnostic I scans (the radioactive iodine I131 collects in and destroys thy- roid cancer cells throughout the body) ● ultrasound scans In October 2003, Medicare and Medicaid added Positron EmissionTomography (PET) to this arsenal for detecting recurrences in select thyroid cancer patients. PET goes beyond the other testing modalities by providing a color-coded account of body chemistry. Recurrences appear visually as areas of higher metabolic activity. According to Robert J. McConnell, MD, Associate Clinical Professor of “PET can affect treatment for Medicine at Columbia University College of Physicians & Surgeons and Co- recurrent thyroid cancer by Director of the New York Thyroid Center, locating lesions throughout “PET is a specialized tool. We use PET to the body that may be image metastatic thyroid cancer for a amenable to therapy.” 2 healthpoints • winter 2004 Approved for the Fight Against Thyroid Cancer PET scans detect areas of increased metabolism in the body. In the scan to the left, thyroid cancer appears as a darkened region in the neck (outlined by the red box). This scan also shows areas of healthy increased metabolic activity, such as the brain, heart, and liver. subset (10-15%) of patients who have Columbia, “PET can affect treatment for elevated thyroglobulin levels, but negative recurrent thyroid cancer by locating I131 scans.” lesions throughout the body that may be How PET Works “When thyroid tumors spread amenable to therapy, such as surgery or throughout the body, they can become directed radiotherapy.” PET scans display color-coded images of less differentiated and no longer take up While Medicare and Medicaid the body’s metabolic and chemical I131 ,” explains William B. Inabnet, MD, currently recommend the use of PET to processes. Before having a PET scan, Chief of Endocrine Surgery at Columbia detect recurrences in thyroid cancers of patients receive an injection of a harm- University Medical Center, NewYork- follicular origin, Dr. Fawwaz predicts that less tracer that attaches to glucose in Presbyterian Hospital and Assistant PET will ultimately be used to detect the body. Cancerous tissue absorbs Professor of Surgery at Columbia recurrences for all types of thyroid cancer. greater quantities of glucose than University College of Physicians & Ultimately, Dr. Inabnet hopes that healthy tissue. Glucose “feeds” the Surgeons. “PET is a great advance because ongoing academic research will enable tumor, allowing it to more rapidly multi- it allows imaging of metastatic thyroid physicians to use PET not only to detect, ply and expand. By revealing areas of lesions by a different mechanism than but also to treat thyroid cancers—much increased glucose consumption in the with I131 .The sensitivity of PET is quite as they use I131 today. body, PET scans can spot active tumors. high in that 60-90% of patients who meet Many other imaging technologies, the screening criteria will have positive For more information about PET for such as MRI (magnetic resonance findings.” thyroid cancer, please contact the imaging) and CT (computed tomography), According to Rashid A. Fawwaz, MD, Columbia Kreitchman PET Center at Professor of Clinical Radiology at 212.923.1555 or [email protected] show the internal structures of the body. By focusing on metabolic changes, PET can often highlight tumors before struc- tural changes appear. CASE STUDY Individuals with thyroid cancer typically undergo a “full-body” PET scan, A physician referred a female patient to Columbia which covers the neck and trunk of the Kreitchman PET Center for a whole-body PET body. The full-body approach enables scan. The woman had previously undergone a total thyroidectomy (removal of physicians to detect whether any tumors the thyroid gland) to treat her follicular thyroid cancer. As part of her follow-up have spread beyond the initial site of the 131 care, she received regular diagnostic I scans and thyroglobulin studies. thyroid. A full-body PET scan typically 131 Radioactive iodine I collects in (and destroys) differentiated thyroid cancer takes less than one hour and only a small cells; the protein thyroglobulin becomes elevated in individuals with thyroid portion of the patient is covered by the cancer. scanner at any time. The radiation Over a year after her thyroidectomy, a test showed that the woman had an exposure is similar to that from an X-ray 131 elevated thyroglobulin level. The diagnostic I scan remained negative, or CT scan. suggesting a recurrence of a less differentiated cancer. A PET scan was ordered to help her physician make a firm diagnosis. The scan showed a recurrence in her right superclavicular area. The woman underwent surgery to remove the recurrence. www.columbiapet.org healthpoints • winter 2004 3 PATIENT PROFILE Glenda Daggert DIABETES CONTINUED FROM P. 1 When 15-year-old Glenda can be very successful. Dr. Goland emphasizes that treatment Daggert was diagnosed with success is completely dependent on a patient’s motivation. diabetes in the early 1960s, “you hid diabetes.” In spite of her Type 1 illness, Glenda went on to earn Formerly called juvenile diabetes, type 1 is an autoimmune disease degrees in physical education and that results from the body’s failure to produce insulin. The disease instructional technology, then occurs when the body’s immune system destroys the pancreatic RENÉ PEREZ taught for several years. She cells that produce insulin. Type 1 usually develops before age 20 married Ira Copperman, moved to New York, and joined and is typically first diagnosed in children, teenagers, or young IBM as a leadership trainer, a position she still holds today.
Load more

Recommended publications
  • When Is It Minimally Invasive?
    ORIGINAL ARTICLE Incision Length for Standard Thyroidectomy and Parathyroidectomy When Is It Minimally Invasive? Laurent Brunaud, MD; Rasa Zarnegar, MD; Nobuyuki Wada, MD; Philip Ituarte, PhD; Orlo H. Clark, MD; Quan-Yang Duh, MD Hypothesis: Current techniques for open conven- parathyroidectomy (PϽ.001). It was 4.1 cm for bilateral tional thyroidectomy or parathyroidectomy have evolved parathyroid exploration, but was reduced to 3.2 and 2.8 to enable a shorter incision (main proposition), and the cm for unilateral (PϽ.001) and focal (PϽ.001) explora- length of the incision is influenced by objective factors. tions, respectively. By multiple regression analysis, thy- roid specimen volume and patient body mass index were Design: Case series. independent predictors of incision length in thyroidec- tomy. Extent of exploration and resident training level Setting: University referral center. were independent predictors of incision length in parathyroidectomy. Patients and Intervention: Retrospective study of the most recent 200 primary consecutive routine thyroid and Conclusions: Current techniques for open conven- parathyroid operations (excluding neck dissections). tional thyroidectomy or parathyroidectomy have evolved to enable a shorter incision. Thyroid volume, patient body Main Outcome Measures: The length of incision was mass index, extent of the planned parathyroid explora- routinely measured with a ruler before the incision. tion, and the resident clinical training stage are impor- Univariate and multivariate analysis was performed to dis- tant variables for incision length in open operation and tinguish variables affecting length of incision. should be taken into account when minimally invasive thyroidectomy and parathyroidectomy are evaluated. Results: Mean length of the incision was 5.5 cm for to- tal thyroidectomy, 4.6 cm for lobectomy, and 3.5 cm for Arch Surg.
    [Show full text]
  • Analysis of the Role of Thyroidectomy and Thymectomy in the Surgical Treatment of Secondary Hyperparathyroidism
    Am J Otolaryngol 40 (2019) 67–69 Contents lists available at ScienceDirect Am J Otolaryngol journal homepage: www.elsevier.com/locate/amjoto Analysis of the role of thyroidectomy and thymectomy in the surgical ☆ treatment of secondary hyperparathyroidism T Mateus R. Soares, Graziela V. Cavalcanti, Ricardo Iwakura, Leandro J. Lucca, Elen A. Romão, ⁎ Luiz C. Conti de Freitas Division of Head and Neck Surgery, Department of Ophthalmology, Otolaryngology, Head and Neck Surgery, Ribeirao Preto Medical School, University of Sao Paulo, Brazil ARTICLE INFO ABSTRACT Keywords: Purpose: Parathyroidectomy can be subtotal or total with an autograft for the treatment of renal hyperpar- Parathyroidectomy athyroidism. In both cases, it may be extended with bilateral thymectomy and total or partial thyroidectomy. Hyperparathyroidism Thymectomy may be recommended in combination with parathyroidectomy in order to prevent mediastinal Thymectomy recurrence. Also, the occurrence of thyroid disease observed in patients with hyperparathyroidism is poorly Thyroidectomy understood and the incidence of cancer is controversial. The aim of the present study was to report the ex- perience of a single center in the surgical treatment of renal hyperparathyroidism and to analyse the role of thyroid and thymus surgery in association with parathyroidectomy. Materials and methods: We analysed parathyroid surgery data, considering patient demographics, such as age and gender, and surgical procedure data, such as type of hyperparathyroidism, associated thyroid or thymus surgery, surgical duration and mediastinal recurrence. Histopathological results of thyroid and thymus samples were also analysed. Results: Medical records of 109 patients who underwent parathyroidectomy for secondary hyperparathyroidism were reviewed. On average, thymectomy did not have impact on time of parathyroidectomy (p = 0.62) even when thyroidectomy was included (p = 0.91).
    [Show full text]
  • Use of Dexmedetomidine in a Parturient with Multiple Endocrine Neoplasia Type 2A Undergoing Adrenalectomy and Thyroidectomy
    PRACTICE CASE REPORT Use of Dexmedetomidine in a Parturient With Multiple Endocrine Neoplasia Type 2A Undergoing Adrenalectomy and Thyroidectomy: A Case Report Amanda L. Faulkner, MD, Eric Swanson, MD, Thomas L. McLarney, MD, Cortney Y. Lee, MD, and Annette Rebel, MD * * * † * 08/15/2018 on BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWnYQp/IlQrHD3yRlXg5VZA8uqNuqWFo8dRhJiNZRTFLkCeIa0nEMHM2KbYm37VRaE3A== by https://journals.lww.com/aacr from Downloaded Dexmedetomidine is a selective α2-agonist, frequently used in perioperative medicine as anes- thesia adjunct. The medication carries a Food and Drug Administration pregnancy category C Downloaded designation and is therefore rarely used for parturients undergoing nonobstetric surgery. We are reporting the use of dexmedetomidine in the anesthetic management of a parturient undergoing minimally invasive unilateral adrenalectomy for pheochromocytoma during the second trimester from https://journals.lww.com/aacr of pregnancy. Additionally, because of the multiple endocrine neoplasia type 2A constellation with diagnosis of medullary thyroid cancer, the patient underwent a total thyroidectomy 1 week after the adrenalectomy. (A&A Practice. XXX;XXX:00–00.) exmedetomidine is a selective α2-agonist, fre- CASE REPORT by BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWnYQp/IlQrHD3yRlXg5VZA8uqNuqWFo8dRhJiNZRTFLkCeIa0nEMHM2KbYm37VRaE3A== quently used in perioperative medicine. It has A 34-year-old gravida 3 para 2 woman (body weight, 61 Dfound favor in this setting because of its sedative kg;
    [Show full text]
  • Pituitary Apoplexy After Subtotal Thyroidectomy In
    CASE REPORT Pituitary Apoplexy after Subtotal Thyroidectomy in an Acromegalic Patient with a Large Goiter Kazunobu Kato, Masakazu Nobori*, Yoshihiro Miyauchi, Motoki Ohnisi, Shyoji Yoshida, Shigeru Oya**, Shin Tomita** and Tomoshige Kino*** A case of pituitary apoplexy occurring after subtotal thyroidectomy in an acromegalic woman with a large adenomatous goiter is described. The patient had severe apnea because the large goiter was causing airway compression. Prior to the planned hypophysectomy, a subtotal thyroidectomy was performed to relieve tracheal stenosis. Shortly after the operation, the patient developed a headache that lasted for several days. The serum levels of growth hormoneand somatomedin-C spontaneously normalized seventeen days after this episode and have remained normal for two years. Pituitary apoplexy was thought to have caused the observed results without deterioration of the pituitary function. (Internal Medicine 35: 472-477, 1996) Key words: acromegaly, thyroid goiter, airway obstruction, diabetes mellitus Introduction and noticed enlargement of her hands. In February 1991, thirst and general fatigue developed and she consulted a local physi- Pituitary apoplexy is an uncommonevent, sometimes fatal, cian and was found to have diabetes mellitus and an abnormal but sometimes it induces complete reversal of acromegaly. It mass adjacent to the right side of the trachea, according to chest occurs in various situations, such as during the course of drug X-ray films. The patient, an unmarried desk clerk, was referred therapy for pituitary adenoma,during pregnancy, or after to us, with the complaint ofdyspnea that was moresevere lying cholecystectomy. However,there are no reports documenting down than in the sitting position. She had excessive nocturnal pituitary apoplexy after thyroidectomy.
    [Show full text]
  • Icd-9-Cm (2010)
    ICD-9-CM (2010) PROCEDURE CODE LONG DESCRIPTION SHORT DESCRIPTION 0001 Therapeutic ultrasound of vessels of head and neck Ther ult head & neck ves 0002 Therapeutic ultrasound of heart Ther ultrasound of heart 0003 Therapeutic ultrasound of peripheral vascular vessels Ther ult peripheral ves 0009 Other therapeutic ultrasound Other therapeutic ultsnd 0010 Implantation of chemotherapeutic agent Implant chemothera agent 0011 Infusion of drotrecogin alfa (activated) Infus drotrecogin alfa 0012 Administration of inhaled nitric oxide Adm inhal nitric oxide 0013 Injection or infusion of nesiritide Inject/infus nesiritide 0014 Injection or infusion of oxazolidinone class of antibiotics Injection oxazolidinone 0015 High-dose infusion interleukin-2 [IL-2] High-dose infusion IL-2 0016 Pressurized treatment of venous bypass graft [conduit] with pharmaceutical substance Pressurized treat graft 0017 Infusion of vasopressor agent Infusion of vasopressor 0018 Infusion of immunosuppressive antibody therapy Infus immunosup antibody 0019 Disruption of blood brain barrier via infusion [BBBD] BBBD via infusion 0021 Intravascular imaging of extracranial cerebral vessels IVUS extracran cereb ves 0022 Intravascular imaging of intrathoracic vessels IVUS intrathoracic ves 0023 Intravascular imaging of peripheral vessels IVUS peripheral vessels 0024 Intravascular imaging of coronary vessels IVUS coronary vessels 0025 Intravascular imaging of renal vessels IVUS renal vessels 0028 Intravascular imaging, other specified vessel(s) Intravascul imaging NEC 0029 Intravascular
    [Show full text]
  • Volume-Based Trends in Thyroid Surgery
    ORIGINAL ARTICLE Volume-Based Trends in Thyroid Surgery Christine G. Gourin, MD; Ralph P. Tufano, MD; Arlene A. Forastiere, MD; Wayne M. Koch, MD; Timothy M. Pawlik, MD, MPH; Robert E. Bristow, MD Objective: To characterize contemporary patterns of thy- pitalization (0.44; PϽ.001), and had a lower incidence roid surgical care and variables associated with access to of recurrent laryngeal nerve injury (0.46; P=.002), hy- high-volume care. pocalcemia (0.62; PϽ.001), and thyroid cancer surgery (0.89; P=.01). After controlling for other variables, thy- Design: Cross-sectional analysis. roid surgery in 2000-2009 was associated with high- volume surgeons (OR, 1.76; PϽ.001), high-volume hos- Setting: Maryland Health Service Cost Review Com- pitals (2.93; P Ͻ .001), total thyroidectomy (2.67; mission database. PϽ.001), and neck dissection (1.28; P=.02) but was less likely to be performed for cancer (0.83; PϽ.001). Patients: Adults who underwent surgery for thyroid dis- ease in Maryland between January 1, 1990, and July 1, Conclusions: The proportion of thyroid surgical pro- 2009. cedures performed by high-volume surgeons and in high- volume hospitals increased significantly from 1990- Results: Overall, 21 270 thyroid surgical procedures were 1999 to 2000-2009, with an increase in total performed by 1034 surgeons at 51 hospitals. Proce- thyroidectomy and neck dissection. Surgeon volume was dures performed by high-volume surgeons increased from significantly associated with complication rates. Thy- 15.7% in 1990-1999 to 30.9% in 2000-2009 (odds ratio roid cancer surgery was less likely to be performed by [OR], 3.69; PϽ.001), while procedures performed at high- high-volume surgeons and in 2000-2009 despite an in- volume hospitals increased from 11.9% to 22.7% (3.46; crease in surgical cases.
    [Show full text]
  • Thyroid & Parathyroid Surgery
    Thyroid & Parathyroid Surgery – Frequently Asked Questions How long will the operation take? What about neck stiffness and exercises? Thyroid and parathyroid operations generally take between one to Some neck stiffness is common as a result of the prolonged three hours. extension (backward tilting) of the head under the anaesthetic. The exercises recommended will reduce it but it may last for some Will I need a general anaesthetic? weeks and require physiotherapy as well. This type of surgery requires a general anaesthetic in order to stop Will my parathyroid glands be taken out with my thyroid? muscle movement during the delicate dissection. Often the anaesthetic is supplemented by local anaesthetic or a nerve block, If you are having thyroid surgery ("thyroidectomy") then every this may result in you having a numb face and ear for 24 hours attempt is made to preserve all your parathyroid glands. Mostly afterwards. they are left in place with their blood supply attached but, if that is not technically possible, they may need to be removed and How long will my incision be and where will it be placed? transplanted into the adjacent muscle. Sometimes very small parathyroid glands are buried under the thyroid capsule and For open thyroid or parathyroid surgery the scar is a curved line in cannot be identified at operation and so get taken out with the the "collar" position, about 2cm above the collar bone. The length thyroid specimen. Transplanted parathyroid glands take between varies depending on the size of the lump removed. For minimally 6 weeks to 6 months to recover, however the body can generally invasive surgery the scar is only 2 to 3cm long and is placed on get by with just part of one parathyroid gland if necessary.
    [Show full text]
  • Thyroidectomy –
    Thyroidectomy – an operation to remove all or part of the thyroid gland Information for patients page 2 What is the thyroid gland? The thyroid gland is an endocrine gland which makes hormones that are released into the bloodstream. These hormones affect cells and tissues in other parts of the body and help them to function normally. The thyroid is made up of two lobes, each about half the size of a plum. The two lobes lie on either side of your windpipe, with the gland as a whole lying just below your Adam’s apple. The thyroid gland produces three hormones, that are released into the bloodstream: • thyroxine, often called T4 • triiodothyronine, often called T3. In the body, T4 is converted into T3 and this is what influences the way cells and tissues work. • calcitonin – this is involved in controlling calcium levels in the blood. With medullary thyroid cancer (MTC), too much calcitonin is produced, however this does not lead to any significant change in calcium levels. Thyroxine and T3 can both be replaced by medication and the body can function perfectly well with little or no calcitonin. Thyroid hormones T3 and T4 help to control the speed of body processes – otherwise known as your metabolic rate. If too much of these thyroid hormones is released, your body starts to work faster than normal and you develop ‘hyperthyroidism’. This would make you feel overactive and anxious, hungrier than usual, and you would lose weight. However, if too little of these thyroid hormones is produced, your body will start to work slower than normal and you develop ‘hypothyroidism’.
    [Show full text]
  • ICD-9-CM Procedure Version 23
    Procedure Code Set General Equivalence Mappings ICD-10-PCS to ICD-9-CM and ICD-9-CM to ICD-10-PCS 2008 Version Documentation and User’s Guide Preface Purpose and Audience This document accompanies the 2008 update of the Centers for Medicare and Medicaid Studies (CMS) public domain code reference mappings of the ICD-10 Procedure Code System (ICD-10- PCS) and the International Classification of Diseases 9th Revision (ICD-9-CM) Volume 3. The purpose of this document is to give readers the information they need to understand the structure and relationships contained in the mappings so they can use the information correctly. The intended audience includes but is not limited to professionals working in health information, medical research and informatics. General interest readers may find section 1 useful. Those who may benefit from the material in both sections 1 and 2 include clinical and health information professionals who plan to directly use the mappings in their work. Software engineers and IT professionals interested in the details of the file format will find this information in Appendix A. Document Overview For readability, ICD-9-CM is abbreviated “I-9,” and ICD-10-PCS is abbreviated “PCS.” The network of relationships between the two code sets described herein is named the General Equivalence Mappings (GEMs). • Section 1 is a general interest discussion of mapping as it pertains to the GEMs. It includes a discussion of the difficulties inherent in linking two coding systems of different design and structure. The specific conventions and terms employed in the GEMs are discussed in more detail.
    [Show full text]
  • The Relationship Between Bone Metabolism, Melatonin and Other Hormones in Sham-Operated and Pinealectomized Rats
    ENDOCRINE REGULATIONS, VOL. 37, 211–224, 2003 211 THE RELATIONSHIP BETWEEN BONE METABOLISM, MELATONIN AND OTHER HORMONES IN SHAM-OPERATED AND PINEALECTOMIZED RATS Z. OSTROWSKA, B. KOS-KUDLA1, M. NOWAK1, E. SWIETOCHOWSKA, B. MAREK1, J. GORSKI, D. KAJDANIUK1, K. WOLKOWSKA Department of Clinical Biochemistry, 1Department of Pathophysiology and Endocrinology, The Medical University of Silesia, Zabrze, Poland E-mail: [email protected] Objective. The influence of pinealectomy and long-term melatonin (MEL) administration on circadian oscillations of selected biochemical markers of bone metabolism [serum alkaline phos- phatase (ALP) activity, carboxyterminal propeptide type I procollagen (PICP) and carboxyterminal telopeptide type I collagen (ICTP) concentrations as well as urinary excretion of hydroxyproline (HYP) and Ca] and possible involvement of circadian secretion of IGF-I, parathyroid, thyroid, adrenal cortex and gonads function in this mechanism was evaluated. Methods. Studies were performed in 192 adult male Wistar rats weighing 145±9 g which were subjected to pinealectomy or sham operation. In half of the animals from each group MEL (Sigma, USA) in a dose of 50 mg/100 g b.w. was administered intraperitonealy (daily between 17.00 and 18.00 h for a 4-week period). Material for studies (blood and urine) was collected every 3 hours during a day. Hormones, PICP and ICTP concentrations were determined with the use of RIA meth- ods, whereas ALP, HYP and Ca values - spectrophotometrically. Results. The study has shown that pinealectomy had an inducing, while exogenous MEL a suppressing effect upon the level of investigated biochemical markers of bone metabolism. Fur- thermore, substantial changes in the values of amplitude and phase of their circadian oscillations were shown.
    [Show full text]
  • (CCSR) for ICD-10-PCS PROCEDURES, V2021.1
    USER GUIDE: CLINICAL CLASSIFICATIONS SOFTWARE REFINED (CCSR) FOR ICD-10-PCS PROCEDURES, v2021.1 Issued December 2020 Agency for Healthcare Research and Quality Healthcare Cost and Utilization Project (HCUP) Phone: (866) 290-HCUP (4287) Email: [email protected] Website: www.hcup-us.ahrq.gov TABLE OF CONTENTS What’s New in v2021.1 of the Clinical Classifications Software Refined (CCSR) for ICD-10-PCS Procedures? .............................................................................................................................. 1 Introduction ................................................................................................................................ 2 Comparison of the CCSR for ICD-10-PCS, the Beta Versions of the CCS for ICD-10-PCS, and the CCS for ICD-9-CM ............................................................................................................... 3 Description of the CCSR for ICD-10-PCS .................................................................................. 4 Understanding the Taxonomy of the ICD-10-PCS Procedure Codes ...................................... 4 The Structure of the CCSR for ICD-10-PCS ........................................................................... 7 General Assignment Guidelines .........................................................................................11 Using the CCSR to Trend ICD-10-PCS Across Data Years .......................................................12 Using the Downloadable CCSR Files ........................................................................................12
    [Show full text]
  • NACB LMPG Thyroid Disease
    Volume 13/2002 The National Academy of Clinical Biochemistry Presents LABORATORY MEDICINE PRACTICE GUIDELINES LABORATORY SUPPORT FOR THE DIAGNOSIS OF THYROID DISEASE ARCHIVED NACB: Laboratory Support for the Diagnosis and Monitoring of Thyroid Disease Laurence M. Demers, Ph.D., F.A.C.B.and Carole A. Spencer Ph.D., F.A.C.B. LABORATORY MEDICINE PRACTICE GUIDELINES Laboratory Support for the Diagnosis and Monitoring of Thyroid Disease Table of Contents Section I. Foreword and Introduction Section 2. Pre-analytic factors Section 3. Thyroid Tests for the Laboratorian and Physician A. Total Thyroxine (TT4) and Total Triiodothyronine (TT3) methods B. Free Thyroxine (FT4) and Free Triiodothyronine (FT3) tests C. Thyrotropin/ Thyroid Stimulating Hormone (TSH) measurement D. Thyroid Autoantibodies: • Thyroid Peroxidase Antibodies (TPOAb) • Thyroglobulin Antibodies (TgAb) • Thyrotrophin Receptor Antibodies (TRAb) E. Thyroglobulin (Tg) Measurement F. Calcitonin (CT) and ret Proto-oncogene G. Urinary Iodide Measurement H. Thyroid Fine Needle Aspiration (FNA) and Cytology I. Screening for Congenital Hypothyroidism Section 4. The Importance of the Laboratory - Physician Interface Appendices and Glossary References Editors: Laurence M. Demers, Ph.D., F.A.C.B. Carole A. Spencer Ph.D., F.A.C.B. Guidelines Committee: The preparation of this revised monograph was achieved with the expert input of the editors, members of the guidelines committee, experts who submitted manuscripts for each section and many expert reviewers, who are listed in Appendix A. The material in this monograph represents the opinions of the editors and does not represent the official position of the National Academy of Clinical Biochemistry or any of the co-sponsoring organizations. The National Academy of Clinical Biochemistry is the official academy of the American Association of Clinical Chemistry.
    [Show full text]